Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660

Control of Regulatory T Cell Development by the Transcription Factor Foxp3

Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187

The Role of Tumoral FOXP3 on Cell Proliferation, Migration, and Invasion in Gastric Cancer

Zhang, L., Xu, J., Zhang, X., Zhang, Y., Wang, L., Huang, X., & Xu, Z. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479442 · Cited by 4,090

Enhancement of Antitumor Immunity by CTLA-4 Blockade

Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955

An essential role for Scurfin in CD4+CD25+ T regulatory cells

Khattri, R., Cox, T., Yasayko, S.-A., & Ramsdell, F. (2003) · Nature Immunology · doi:10.1038/ni909 · Cited by 2,860

Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4

Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766

Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4

Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233

CTLA-4 can function as a negative regulator of T cell activation

Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222

CD4+CD25+ suppressor T cells: more questions than answers

Shevach, E. M. (2002) · Nature reviews. Immunology · doi:10.1038/nri821 · Cited by 2,097

The Role of Nanomedicine in the Treatment of Neurodegenerative Disorders

Rahaman, S. T. (2019) · Springer eBooks · doi:10.1007/978-3-030-30930-5_3 · Cited by 3

Ipilimumab-Induced Hypophysitis May Not Affect All Pituitary Cell Lines: A Case Report

Kotwal, A., Rao, S. N., & Haas, R. A. (2015) · Journal of Endocrinology and Metabolism · doi:10.14740/jem287w · Cited by 3

Pharmacogenetics and Pharmacogenomics I: Linking Diagnostic Classification to Therapeutic Decisions

Murphy, M. J., Pincelli, C., Hoss, D. M., & Borroni, R. G. (2011) · Humana Press eBooks · doi:10.1007/978-1-60761-171-4_21 · Cited by 3

Immunologic targeting: how to channel a minimal response for maximal outcome

Slovin, S. F. (2006) · Current Opinion in Urology · doi:10.1097/01.mou.0000193396.00340.e5 · Cited by 3

Editorial on "Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccination for Recurrent Glioblastoma: A Phase II, Single Arm Trial"

Sampson, J. H., & Vlahovic, G. (2014) · Neuro-Oncology · doi:10.1093/neuonc/not311 · Cited by 3

Ipilimumab Associated Autoimmune Alveolitis Responding to Corticosteroids

Rao, A. R., & Grumett, S. A. (2012) · Journal of Medical Cases · doi:10.4021//jmc.v4i1.886 · Cited by 2

Improving of Antitumor Immunity and Therapeutic Efficacy of Cancer Vaccines and Adoptive Immunotherapies Using Monoclonal Antibodies

Khansari, N. (2015) · MOJ Immunology · doi:10.15406/moji.2015.02.00062 · Cited by 2

Systematic Review on the Efficacy and Safety of Immune Checkpoint Inhibition in Renal Cell Carcinoma

Lyu, C., Li, W., Liu, S., Gao, S., Zhang, H., Hao, L., Yu, H., Wei, W., Song, J., Yang, Y., et al. (2018) · Future Oncology · doi:10.2217/fon-2018-0193 · Cited by 2

Regulatory T Cells Nanoextinguisher to Manipulate Multiple Immune Evasion for Immunotherapy

Zhao, C., Wang, C., Wang, R., Shan, W., Wang, W., & Deng, H. (2024) · ACS Nano · doi:10.1021/acsnano.4c04663 · Cited by 2

Pericardial Effusion with Tamponade, an Immune-Related Adverse Event Associated with Nivolumab Therapy: A Case Report and Review of the Literature

Naime, F. D. F. (2018) · Journal of Cancer Therapy · doi:10.4236/jct.2018.912085 · Cited by 2

Frontiers in Cancer Immunotherapy

Murphy, J. F. (2014) · Springer eBooks · doi:10.1007/978-3-662-44946-2_1 · Cited by 2

Analysis of cutaneous melanoma in the province of Vojvodina.

Jovanovic, M., Bogdanovic, G., Mijatović-Jovanović, V., Jeremić, P., & Nikolic, E. A. (2009) · PubMed · Cited by 2

The Italian Network for Tumor Biotherapy (NIBIT): Getting together to push the field forward

Maio, M., Nicolay, H. J. M., Ascierto, P. A., Belardelli, F., Camerini, R., Colombo, M. P., Queirolo, P., Ridolfi, R., Russo, V. E. A., Anzalone, L., et al. (2008) · Journal of Translational Medicine · doi:10.1186/1479-5876-6-8 · Cited by 2

Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab

Graziani, G., Tentori, L., & Navarra, P. (2013) · Springer eBooks · doi:10.1007/978-3-7091-1300-4_10 · Cited by 2

SANTAVAC ™: A Novel Universal Antigen Composition for Developing Cancer Vaccines

Balashova, E. E., & Lokhov, P. G. (2016) · Recent Patents on Biotechnology · doi:10.2174/1872208309666161130140535 · Cited by 2

Cyclosporine but not acitretin for psoriasis exacerbation and general Myalgia induced by Pembrolizumab in a patient with advanced esophageal cancer

Lee, C., & Tseng, Y.-J. (2019) · Dermatologica Sinica · doi:10.4103/ds.ds_45_18 · Cited by 2

Nivolumab-induced immune-mediated neurotoxicity in Hodgkin lymphoma

Lopez, J., Yarlagadda, N., Gheith, Z., Mohan, M., & Sasapu, A. (2019) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2019.1668719 · Cited by 2

Renale Toxizitäten von Checkpoint-Inhibitoren bei onkologischen Therapien

Anker, S., Hannemann, L., Benesova, K., Eckert, C., Jordan, K., Müller‐Tidow, C., Schulte, K., & Neuendorff, N. R. (2019) · Der Nephrologe · doi:10.1007/s11560-019-00390-w · Cited by 2

Relationship of Hypothyroidism and Immune Response to Pegylated IL-10/nivolumab

Albrethsen, M., Creeden, J. F., Morand, S. M., DeBiase, J. M., Berry, B. M., Stanbery, L., Edelman, G. M., & Nemunaitis, J. J. (2020) · Immunotherapy · doi:10.2217/imt-2020-0016 · Cited by 2

Approach to Reporting Inflammatory Bowel Disease Biopsies

Feakins, R. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781316823026.025 · Cited by 2

Diverticular Disease, Mucosal Prolapse, and Related Conditions

Adamczyk, L. A., & Shepherd, N. A. (2020) · Cambridge University Press eBooks · doi:10.1017/9781316823026.027 · Cited by 2

Dendritic Cell Vaccines

Adams, S., Bhardwaj, N., & O’Neill, D. W. (2007) · Springer eBooks · doi:10.1007/978-1-4020-6087-8_11 · Cited by 2

Microscopic Colitis

Loughrey, M. B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781316823026.021 · Cited by 2

Immunotherapy for Advanced Melanoma

Roman, R.-A. (2011) · Clinical journal of oncology nursing · doi:10.1188/11.cjon.e58-e65 · Cited by 2

Overcoming Cancer Tolerance with Immune Checkpoint Blockade

Clifton, G. T., Mittendorf, E. A., & Peoples, G. E. (2014) · Springer eBooks · doi:10.1007/978-3-662-44946-2_6 · Cited by 2

Therapeutic Antibodies in Clinical Use and Leading Clinical Candidates

Zhang, N., Williams, B. R., Lü, P., An, Z., & Chin, C. (2009) · Wiley eBooks · doi:10.1002/9780470485408.ch31 · Cited by 2

Does CTLA4 Influence the Suppressive Effect of CD25+CD4+ Regulatory T Cells?

Ferretti, G., Felici, A., Pino, M. S., & Cognetti, F. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.5515 · Cited by 2

Differential targeting of tryptophan catabolism in tumors and in tumor-draining lymph nodes by stereoisomers of the IDO inhibitor 1-methyl-tryptophan

Muller, A. J., Metz, R. A., & Prendergast, G. C. (2007) · International Congress Series · doi:10.1016/j.ics.2007.07.042 · Cited by 3

First world meeting of interdisciplinary melanoma/skin cancer centers

(2007) · Archives of Dermatological Research · doi:10.1007/s00403-007-0771-8 · Cited by 2

Function and Therapeutic Intervention of Regulatory T Cells in Immune Regulation

Liu, Y., Hou, T., & Hao, H. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.104914 · Cited by 1

Dietary Addition of Betaine on the Performance of Broilers Fed with Diets with a Reduction in Methionine and Choline

Kumar, A., Kulkarni, R. C., Awandkar, S. P., Gaikwad, N. Z., Khode, N. V., Chavhan, S. G., & Gadegaonkar, G. M. (2024) · Journal of Advances in Biology & Biotechnology · doi:10.9734/jabb/2024/v27i6959 · Cited by 1

Mutations Associated With High-Grade irAEs in NSCLC Patients Receiving Immunotherapies

Smith-Oliver, M. R., Wang, Y., Dixon, C. B., D'Agostino, R., Liu, Y., Ruiz, J., Oliver, G., Miller, L. D., Topaloĝlu, Ü., Chan, M. D., et al. (2024) · Clinical Lung Cancer · doi:10.1016/j.cllc.2024.07.003 · Cited by 1

Oncofertility pharmacovigilance in women receiving immune checkpoint inhibitors: Reproductive risks, fertility preservation, and pregnancy outcomes

Shi, J., Han, D.-L., Jiang, H., Ge, Y., Liu, Q., Zhang, J., Zhang, X.-N., & Zhao, J. (2026) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2026.104894 · Cited by 1

Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma: An Overview

Tarhini, A. A., & Kirkwood, J. M. (2011) · Springer eBooks · doi:10.1007/978-1-60761-433-3_23 · Cited by 1

Toxicities of New Drugs for Melanoma Treatment and their Management

Savoia, P., & Fava, P. (2015) · InTech eBooks · doi:10.5772/59860 · Cited by 1

Targeting Immunological Synapse: New Horizons in Immunotherapy for Cancer

Chmielowski, B., & Ribas, A. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-087-8_48 · Cited by 1

Gezielte Therapie: alte und neue Hoffnungsträger

Hochhaus, A., Lüftner, D., & Mackensen, A. (2013) · Oncology Research and Treatment · doi:10.1159/000351997 · Cited by 1

Ovarian cancer vaccine trials and tribulations

Buckanovich, R. J. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.1.103 · Cited by 1

Efectos secundarios cutáneos de los nuevos fármacos antineoplásicos

Aranegui, B., Lara, P. E., & Jiménez‐Reyes, J. (2015) · Piel · doi:10.1016/j.piel.2014.12.007 · Cited by 1

Immunotherapy in Renal Cell Carcinoma

Cudris, J., & Merchan, J. R. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8809-5_8 · Cited by 1

Negative Regulators in Cancer Immunology and Immunotherapy

Zimmermann, W., & Kammerer, R. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-980-2_11 · Cited by 1

Altered Signal Transduction Pathways in Melanoma

Lau, E. K., & Ronai, Z. A. (2011) · Springer eBooks · doi:10.1007/978-3-7091-0371-5_7 · Cited by 1

Emerging Biomarkers During Clinical Development of Anti-CTLA4 Antibody Therapy

Ku, G. Y., Kyi, C., & Yuan, J. D. (2014) · Springer eBooks · doi:10.1007/978-3-662-44946-2_24 · Cited by 1

Ipilimumab et cancer bronchique métastatique : peut-on changer l’histoire naturelle de la maladie ?

Boyer, A., Greillier, L., Barazzutti, H., Tomasini, P., & Barlési, F. (2015) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2014.12.006 · Cited by 1

Immunothérapie : un nouveau paradigme dans la prise en charge du cancer bronchique non à petites cellules

Gauvain, C., Léna, H., Corre, R., Ricordel, C., Vinas, F., & CHOUAID, C. (2016) · ONCOLOGIE · doi:10.1007/s10269-016-2633-5 · Cited by 1

Dendritic Cell Vaccines

Durham, N. M., & Drake, C. G. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-394296-8.00018-x · Cited by 1

Two Patients with Non-small Cell Lung Cancer Developed Thyroid Dysfunction Accompanied by the Emergence of Anti-thyroglobulin Antibodies During Nivolumab Therapy

Yoshihara, M., Kimura, R., Kunii, E., Mori, Y., Horiuchi, M., & Akita, K. (2017) · Haigan · doi:10.2482/haigan.57.308 · Cited by 1

Pathologic Response of the Gastrointestinal Tract to Toxicants

McCarthy, A. J., & Sheahan, K. D. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.95672-1 · Cited by 1

Drug-Induced Gastrointestinal Disease

McCarthy, A. J., & Sheahan, K. D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781316823026.006 · Cited by 1

Infectious Disorders of the Lower Gastrointestinal Tract

Panarelli, N. C. (2020) · Cambridge University Press eBooks · doi:10.1017/9781316823026.019 · Cited by 1

Histology of Gastroesophageal Reflux Disease and Barrett’s Oesophagus

Assarzadegan, N., & Pezhouh, M. K. (2020) · Cambridge University Press eBooks · doi:10.1017/9781316823026.011 · Cited by 1

Gastrointestinal Ischemia and Vascular Disorders

Celli, R., & Zhang, X. (2020) · Cambridge University Press eBooks · doi:10.1017/9781316823026.007 · Cited by 1

Paediatric Conditions

Borralho, P. (2020) · Cambridge University Press eBooks · doi:10.1017/9781316823026.008 · Cited by 1

Gastrointestinal Dysplasia

Svrcek, M., & Feakins, R. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781316823026.009 · Cited by 1

Melanoma

Guggenheim, M., Giovanoli, P., Baumert, B. G., Eigentler, T., Garbe, C., Mangana, J., & Dummer, R. (2010) · Springer eBooks · doi:10.1007/978-3-642-05072-5_23 · Cited by 1

Immunotoxicology of Biopharmaceutics

Haggerty, H. G., Price, K. D., & Shenton, J. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-08-100601-6.02008-1 · Cited by 1

Ipilimumab

Rotte, A., & Bhandaru, M. (2016) · Springer eBooks · doi:10.1007/978-3-319-48066-4_11 · Cited by 1

Immunopathology of Bone and Connective Tissue Cancers and Immunotherapy of Sarcomas

Narayanan, S., & Skitzki, J. J. (2020) · Springer eBooks · doi:10.1007/978-3-030-57949-4_15 · Cited by 1

Interleukin-21 and Cancer Therapy

Davis, I. D., Skak, K., Hunder, N. N. H., Smyth, M. J., & Sivakumar, P. V. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0170-5_3 · Cited by 1

Cancer and the Cellular Immune Response

Hwu, P., Lizee, G. A., & Liu, Y. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4066-6.00051-2 · Cited by 1

Developmental Therapeutics for Gynecologic Cancers: An Overview

Brown, J., & Chu, C. (2016) · Springer eBooks · doi:10.1007/978-3-319-32907-9_6 · Cited by 1

Regulatory T Cells

Thornton, A. M. (2010) · Elsevier eBooks · doi:10.1016/b978-0-08-046884-6.00605-9 · Cited by 1

Inflammatory Bowel Disease Diagnosis

Feakins, R. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781316823026.022 · Cited by 1

Mimics of Inflammatory Bowel Disease

Feakins, R. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781316823026.023 · Cited by 1

Dissociated response related to corticosteroids in lung cancer treated by immunotherapy: A case report

Thomas, Q. D., Sinoquet, L., Maraver, A., & Quantin, X. (2021) · Clinical Case Reports · doi:10.1002/ccr3.3973 · Cited by 1

Renal Toxicity

Abdelrahim, M., & Abudayyeh, A. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-79308-1_16 · Cited by 1

Dermatology (Skin)

Brown, A. M., Masterson, W. M., & Patel, A. B. (2022) · Springer eBooks · doi:10.1007/978-3-031-00241-0_3 · Cited by 1

Treg, Chemokines, and Other Small Molecules: Role in Metastasis and Its Prevention

Oble, D. A., Hodi, F. S., Lauwers, G. Y., Dranoff, G., & Mihm, M. C. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-087-8_24 · Cited by 1

Systemische Therapie des metastasierten Melanoms

Eigentler, T., Meier, F. E., Keilholz, U., Hauschild, A., & Garbe, C. (2010) · Der Onkologe · doi:10.1007/s00761-010-1926-3 · Cited by 1

Treatment of Melanoma

Hofmann, M. A., Sterry, W., & Schwartz, R. A. (2008) · doi:10.1002/9780470696347.ch31 · Cited by 1

Update on monoclonal antibodies for the treatment of cancer

Davis, I. D. (2011) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/j.1743-7563.2011.01384.x · Cited by 1

CTLA-4 Blockade for Prostate Cancer Treatment

Harzstark, A. L., & Fong, L. H. (2010) · Springer eBooks · doi:10.1007/978-1-60327-829-4_30 · Cited by 1

Management of Dysplastic Nevi and Melanomas

Huang, C. L., Marghoob, A. A., & Halpern, A. C. (2005) · Elsevier eBooks · doi:10.1016/b978-0-323-02752-6.50055-9 · Cited by 1

Targeting Extracellular Molecules in Prostate Cancer—Mechanisms to Inhibit Entry into the Cell-Signaling Abyss

Slovin, S. F. (2006) · Translational medicine series · doi:10.3109/9781420019858.005 · Cited by 1

Phase I Trial: SABR and Ipilimumab—Letter

Hiniker, S. M., Reddy, S. A., Swetter, S. M., & Knox, S. J. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2495 · Cited by 1

Kutanes Melanom

Eigentler, T., Mügge, L.-O., Bembenek, A. E., & Garbe, C. (2007) · Der Onkologe · doi:10.1007/s00761-007-1203-2 · Cited by 1

Therapie des metastasierten Melanoms : First-, Second- und pathogenese- orientierte Third-line-Therapien

Rass, K., Tadler, D., & Tilgen, W. (2006) · Der Hautarzt · Cited by 1

Ipilimumab (Yervoy®)

Gordoa, T. A., Vázquez, J. P., & Díaz‐Rubio, E. (2014) · Wiley eBooks · doi:10.1002/9783527682423.ch59 · Cited by 1

Continuing Education

Trinh, V. A. (2008) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/65.24_supplement_9.s16 · Cited by 1

Cancer Vaccines

Laheru, D. A., & Jaffee, E. M. (2007) · The Cancer Handbook · doi:10.1002/9780470025079.chap88.pub2 · Cited by 1

Autoimmunity and Cancer

Whiteside, T. L. (2015) · Springer eBooks · doi:10.1007/978-3-642-27841-9_479-2 · Cited by 1

PPARδ restrains the suppression function of intra-tumoral Tregs by limiting CIITA-MHC II expressionPreprint

Yang, Q., Liang, Y., Inoue-Hatanaka, T., Koh, Z., Ilkenhans, N., Suman, E., Yu, J., & Zheng, Y. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.16.628819 · Cited by 1

Immunobiology and Immune-Based Therapies of Melanoma

Brown, M. R., Ansel, J. C., & Armstrong, C. A. (2008) · Springer eBooks · doi:10.1007/978-1-84800-165-7_17

Dendritic Cells and Coregulatory Signals: Immune Checkpoint Blockade to Stimulate Immunotherapy

Pardoll, D. M. (2007) · Elsevier eBooks · doi:10.1016/b978-012372551-6/50078-x

Immunotherapy of Melanoma: A New Era

Eggermont, A. M. M., Robert, C., & Schadendorf, D. (2011) · Springer eBooks · doi:10.1007/978-3-7091-0371-5_17

Development of Vaccine Therapy for Pancreas Cancer

Le, D. T., Jaffee, E. M., & Laheru, D. A. (2008) · Springer eBooks · doi:10.1007/978-0-387-69252-4_41

Monoclonal Antibody Cancer Treatments in Phase III Clinical Trials

Petrausch, U., & Deckert, P. M. (2014) · doi:10.1002/9783527682423.ch26

CTLA‐4 to overcome immunological tolerance to melanoma

Hodi, F. S. (2011) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/j.1743-7563.2011.01383.x

Immunotoxicology of Biopharmaceutics

Haggerty, H. G., Price, K., & Shenton, J. M. (2010) · Elsevier eBooks · doi:10.1016/b978-0-08-046884-6.00629-1

Immunomodulatory Molecules of the Immune System

Saenger, Y. M., Jenq, R. R., & Perales, M. (2007) · Springer eBooks · doi:10.1007/978-1-4020-6087-8_5

Conception et développement d'outils immunologiques pour suivre et caractériser les réponses immunitaires induites par les vaccins contre l'allergie

Wambre, E. (2008) · HAL

Aktuelle Therapie des malignen Melanoms

Eigentler, T., & Garbe, C. (2008) · Aktuelle Dermatologie · doi:10.1055/s-2008-1077574

Autoimmuninduktion durch pegyliertes Interferon-alpha-2b in Korrelation zur Überlebenszeit bei Mittel- und Hochrisikomelanompatienten

Loquai, C., Schlüter, B., Klötgen, H., Luger, T., Grabbe, S., & Nashan, D. (2008) · Aktuelle Dermatologie · doi:10.1055/s-2007-995760

Immunothérapie des cancers

Quintin‐Colonna, F., Montier, Y., Péré, H., Sandoval, F., Merillon, N., Freyburger, L., Adotévi, O., & Tartour, É. (2009) · Bulletin de l Académie vétérinaire de France · doi:10.4267/2042/48015

Editorial: anticytotoxic T lymphocyte-associated antigen 4 treatment – can melanoma be cured at the expense of autoimmune disorders?

Lejeune, F. J. (2006) · Melanoma Research · doi:10.1097/01.cmr.0000232298.37279.a1

Cutaneous melanoma: an update on therapies

Demierre, M. (2006) · Expert Review of Dermatology · doi:10.1586/17469872.1.1.43

Reply: Controversies on autoimmunity and prognosis in cancer

Whiteside, T. L. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603314

Le traitement pharmacologique du mélanome cutané métastatique

Laforest, M. (2014) · Pharmactuel

Development of cancer immunotherapeutics targeting complement regulatory protein CD55.

Bradley, R. (2007) · UPT. Syiah Kuala University Library (Syiah Kuala University)

Targeting Cancer Associated Fibroblasts for Cancer Immunotherapy

(2014) · Cancer Cell & Microenvironment · doi:10.14800/ccm.80

Intrapatient Dose Escalation of Anti–CTLA-4 Antibody in Patients With Metastatic Melanoma

Maker, A. V., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., Hughes, M. S., Yellin, M. J., Haworth, L. R., Levy, C. L., et al. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000208259.73167.58 · Cited by 264

Autoimmunity in a Phase I Trial of a Fully Human Anti-Cytotoxic T-Lymphocyte Antigen-4 Monoclonal Antibody With Multiple Melanoma Peptides and Montanide ISA 51 for Patients With Resected Stages III and IV Melanoma

Sanderson, K. M., Scotland, R., Lee, P. P., Liu, D., Groshen, S. G., Snively, J., Sian, S., Nichol, G. M., Davis, T. A., Keler, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.128 · Cited by 433

Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II Study

Maker, A. V., Phan, G. Q., Attia, P., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., Haworth, L. R., Levy, C. L., et al. (2005) · Annals of Surgical Oncology · doi:10.1245/aso.2005.03.536 · Cited by 492

CTLA‐4 to overcome immunological tolerance to melanoma

Hodi, F. S. (2011) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/j.1743-7563.2011.01383.x

Cancer regression and autoimmunity induced by cytotoxic t lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575